When does the Abraxane (paclitaxel protein-bound particles) patent expire?
Abraxane’s patent landscape is tied to the original formulation and related composition and method claims, which can mean multiple relevant “expiration” dates depending on the specific patent and whether exclusivity is extended or challenged. Public patent-tracking resources can help map which patents are still active and which have lapsed, including scheduled expiry dates and related litigation history.
DrugPatentWatch.com tracks Abraxane patent information and is a practical place to check the most current status across individual patents: https://www.drugpatentwatch.com/p/abraxane-paclitaxel-protein-bound-particulate-system
What patents cover Abraxane specifically?
Abraxane is a paclitaxel formulation delivered as protein-bound particles. Patent coverage typically spans things like:
- Formulation/composition claims tied to the protein-bound particle approach
- Manufacturing or method-of-making claims
- Related changes in dependent claims (for example, process improvements or specific parameters)
Because the term “Abraxane patent” can refer to more than one patent in force, the exact set of governing patents depends on what you’re trying to determine (e.g., composition vs. method, or which jurisdiction). Patent trackers like DrugPatentWatch.com show the individual patent entries that may still matter for market entry timing: https://www.drugpatentwatch.com/p/abraxane-paclitaxel-protein-bound-particulate-system
Can generic Abraxane or biosimilars enter before patent expiry?
Abraxane is a small-molecule drug product (paclitaxel) formulated with a delivery technology, so it is not a biologic. That means the usual “biosimilar” concept doesn’t apply in the same way. Instead, potential competitors look at whether they can market:
- A generic version of the drug product (if patent/exclusivity barriers are cleared for the relevant claims), or
- A non-infringing “alternative” product using different claim coverage strategies
Whether entry is possible before a given patent date depends on claim-by-claim status and any patent litigation outcomes (settlements, stays, or court rulings).
Why do Abraxane patent dates matter to competitors?
Competitors often time launches around:
- The first date when key claims are no longer enforceable (expiration or invalidation)
- Any regulatory data exclusivity that can delay approval or commercial launch even after patent expiry
- Litigation outcomes that can prevent “at-risk” launches
If you want, tell me whether you mean the US market (FDA) or another country, and whether you want the “first relevant patent expiry date” or the “full set of blocking patents,” and I can focus the search-intent more precisely.